Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia ( CLL ) Care
European Journal of Haematology · 2026-07 · 117 (1) · 9-16
DOI: 10.1111/ejh.70160 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 12.03.2026. Verfasst von Stefano Molica und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hull York Medical School, University of Hull, Hull, UK. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors, Agammaglobulinaemia Tyrosine Kinase, Pyrimidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Covalent Bruton tyrosine kinase inhibitor (cBTKi)‐based regimens have redefined therapy for chronic lymphocytic leukemia (CLL). However, continuous treatment with BTKis can select for therapy resistance, typically associated with BTK C481 mutations and fosfolipasi C gamma 2 (PLCγ2) activation. In addition, continuous BTKi therapy poses challenges for treatment interruptions and dose modifications, with implications for clinical outcomes. Pirtobrutinib, a highly selective, reversible (noncovalent) BTKi, inhibits BTK independently of C481 and maintains sustained target engagement. In patients with cBTKi‐pretreated relapsed/refractory (R/R) CLL, the BRUIN‐CLL‐321 trial demonstrated improved progression‐free survival (PFS) and time to next treatment (TTNT) compared with idelalisib/rituximab or bendamustine/rituximab, accompanied by a favorable tolerability profile. Data from randomized phase III BRUIN‐CLL‐313 and BRUIN‐CLL‐314 trials demonstrate the superiority of pirtobrutinib over chemoimmunotherapy in untreated patients and non‐inferiority to ibrutinib in untreated patients or in patients with R/R disease who had no prior exposure to cBTKis. These data are not sufficient to justify a change in clinical practice; however, they lay the groundwork for a potential future repositioning of pirtobrutinib from the treatment of R/R CLL to earlier lines of therapy. In this review, we address a range of current and prospective aspects of pirtobrutinib‐based therapies: (1) the strengths and limitations of the trial datasets; (2) the biological rationale for frontline noncovalent BTK inhibition; (3) sequencing trade‐offs; and (4) prospective scenarios, including combination strategies and time‐limited regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hull York Medical School, University of Hull, Hull, UK.
- Centre for Biomedicine, Hull York Medical School, Hull, UK.
ORCID-Profile: Stefano Molica, David Allsup
Zitieren
APA
Molica, S., & Allsup, D. (2026). Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia ( CLL ) Care. European Journal of Haematology, 117(1), 9-16. https://doi.org/10.1111/ejh.70160
Vancouver
Molica S, Allsup D. Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia ( CLL ) Care. European Journal of Haematology. 2026;117(1):9-16. doi:10.1111/ejh.70160
BibTeX
@article{Molica2026,
author = {Molica, Stefano and Allsup, David},
title = {Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia ( CLL ) Care},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {9--16},
doi = {10.1111/ejh.70160}
}
EUVIMED